Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02104245




Registration number
NCT02104245
Ethics application status
Date submitted
28/03/2014
Date registered
4/04/2014
Date last updated
26/03/2021

Titles & IDs
Public title
Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension
Secondary ID [1] 0 0
ARD-3150-1202
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non Cystic Fibrosis Bronchiectasis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Ciprofloxacin dispersion for inhalation - Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin

Placebo comparator: Placebo - Liquid formulation of empty liposomes
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to first pulmonary exacerbation (from baseline)
Timepoint [1] 0 0
48 weeks

Eligibility
Key inclusion criteria
* Confirmed diagnosis of non-CF bronchiectasis
* History of P. aeruginosa respiratory infections
* At least two pulmonary exacerbations treated with antibiotics in the previous year
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Have a clinical diagnosis of CF
* Are pregnant

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/05/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2016
Sample size
Target
Accrual to date
Final
304
Recruitment in Australia
Recruitment state(s)
QLD,SA,WA
Recruitment hospital [1] 0 0
- Greenslopes
Recruitment hospital [2] 0 0
- Adelaide
Recruitment hospital [3] 0 0
- Nedlands
Recruitment hospital [4] 0 0
- Perth
Recruitment postcode(s) [1] 0 0
- Greenslopes
Recruitment postcode(s) [2] 0 0
- Adelaide
Recruitment postcode(s) [3] 0 0
- Nedlands
Recruitment postcode(s) [4] 0 0
- Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Nebraska
Country [8] 0 0
United States of America
State/province [8] 0 0
New Hampshire
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New Mexico
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Washington
Country [18] 0 0
United States of America
State/province [18] 0 0
Wisconsin
Country [19] 0 0
Canada
State/province [19] 0 0
British Columbia
Country [20] 0 0
Canada
State/province [20] 0 0
Ontario
Country [21] 0 0
Canada
State/province [21] 0 0
Quebec
Country [22] 0 0
Former Serbia and Montenegro
State/province [22] 0 0
Belgrade
Country [23] 0 0
Former Serbia and Montenegro
State/province [23] 0 0
Knez Selo
Country [24] 0 0
Former Serbia and Montenegro
State/province [24] 0 0
Kragujevac
Country [25] 0 0
Former Serbia and Montenegro
State/province [25] 0 0
Sremska Kamenica
Country [26] 0 0
France
State/province [26] 0 0
Créteil Cedex 01
Country [27] 0 0
France
State/province [27] 0 0
Grenoble cedex
Country [28] 0 0
France
State/province [28] 0 0
Nice Cedex 1
Country [29] 0 0
France
State/province [29] 0 0
Pessac Cedex
Country [30] 0 0
France
State/province [30] 0 0
Rouen Cedex
Country [31] 0 0
France
State/province [31] 0 0
Toulouse cedex 9
Country [32] 0 0
Georgia
State/province [32] 0 0
Kutaisi
Country [33] 0 0
Georgia
State/province [33] 0 0
Tbilisi
Country [34] 0 0
Hungary
State/province [34] 0 0
Budapest
Country [35] 0 0
Hungary
State/province [35] 0 0
Nyiregyhaza
Country [36] 0 0
Hungary
State/province [36] 0 0
Szekesfehervar
Country [37] 0 0
Hungary
State/province [37] 0 0
Torokbalint
Country [38] 0 0
Israel
State/province [38] 0 0
Jerusalem
Country [39] 0 0
Israel
State/province [39] 0 0
Petach Tikva
Country [40] 0 0
Israel
State/province [40] 0 0
Ramat Gan
Country [41] 0 0
Israel
State/province [41] 0 0
Tel-Aviv
Country [42] 0 0
Italy
State/province [42] 0 0
Avellino
Country [43] 0 0
Italy
State/province [43] 0 0
Napoli
Country [44] 0 0
Italy
State/province [44] 0 0
Parma
Country [45] 0 0
Italy
State/province [45] 0 0
Pisa
Country [46] 0 0
Italy
State/province [46] 0 0
San Gerardo
Country [47] 0 0
Italy
State/province [47] 0 0
Terni
Country [48] 0 0
Italy
State/province [48] 0 0
Trieste
Country [49] 0 0
Korea, Republic of
State/province [49] 0 0
Gyeonggi-do
Country [50] 0 0
Korea, Republic of
State/province [50] 0 0
Daegu
Country [51] 0 0
Korea, Republic of
State/province [51] 0 0
Seoul
Country [52] 0 0
New Zealand
State/province [52] 0 0
Auckland
Country [53] 0 0
New Zealand
State/province [53] 0 0
Waikato
Country [54] 0 0
New Zealand
State/province [54] 0 0
Tauranga
Country [55] 0 0
Peru
State/province [55] 0 0
Lima
Country [56] 0 0
Poland
State/province [56] 0 0
Bialystok
Country [57] 0 0
Poland
State/province [57] 0 0
Krakow
Country [58] 0 0
Poland
State/province [58] 0 0
Ruda Slaska
Country [59] 0 0
Poland
State/province [59] 0 0
Warsaw
Country [60] 0 0
Romania
State/province [60] 0 0
Arad
Country [61] 0 0
Romania
State/province [61] 0 0
Bucuresti
Country [62] 0 0
Romania
State/province [62] 0 0
Cluj-Napoca
Country [63] 0 0
Romania
State/province [63] 0 0
Craiova
Country [64] 0 0
Romania
State/province [64] 0 0
Iasi
Country [65] 0 0
Spain
State/province [65] 0 0
Barcelona
Country [66] 0 0
Spain
State/province [66] 0 0
La Coruna
Country [67] 0 0
Spain
State/province [67] 0 0
Lleida
Country [68] 0 0
Spain
State/province [68] 0 0
Valencia
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Cleveland
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Greater Manchester
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Cambridge
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Colchester
Country [73] 0 0
United Kingdom
State/province [73] 0 0
Cottingham
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Lancaster
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Leeds
Country [76] 0 0
United Kingdom
State/province [76] 0 0
London
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Manchester
Country [78] 0 0
United Kingdom
State/province [78] 0 0
North Sheilds
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Southampton
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Telford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Aradigm Corporation
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Grifols Therapeutics LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT02104245